US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
36 deals · US$3.6bndisclosed · Pharma Services · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Sep 2026 | Lifecore Biomedical | – | Webster Equity Partners | Acquisition | Announced | 663.7 | Pharma Services+2 | Bourne Capital Partners (sell-side)Craig-Hallum (sell-side)Ballard Spahr (sell-side)Zukerman Gore Brandeis & Crossman (sell-side)Morgan Stanley (buy-side)Goodwin (buy-side) |
| Sep 2026 | MLM Medical Labs | – | Labcorp | Acquisition | Announced | – | Clinical Trial Services+1 | William BlairEvercore (buy-side)Pierson Ferdinand (buy-side)Hogan Lovells Cadwalader (buy-side) |
| Sep 2026 | New Zealand Clinical Research Group (NZCR) | – | Advent | Acquisition | Announced | – | Clinical Trial Services | Cameron Partners (buy-side) |
| Sep 2026 | Ambit RD | – | Danforth Health | Acquisition | Announced | – | Pharma Services+1 | Clearsight Advisors (sell-side) |
| Sep 2026 | Firma Data Services | Firma Clinical Research | Everest Clinical Research | Asset sale | Completed | – | Clinical Trial Services+1 | Edgemont Partners (sell-side) |
| Sep 2026 | Cellipont Bioservices | – | – | Merger | Completed | – | Pharma Services+2 | William Blair |
| Sep 2026 | Prolytix | Edgewater | VION | Acquisition | Announced | – | Pharma Services+1 | Stout (sell-side) |
| Aug 2026 | Precision Medicine Group | Blackstone | McKesson | Acquisition | Announced | 2,250.0 | Clinical Trial Services+1 | Debevoise & Plimpton (sell-side)Centerview Partners (sell-side)Davis Polk (buy-side) |
| Aug 2026 | ZEPHYRx | – | a Leading Global CRO | Acquisition | Completed | – | Healthcare Software+1 | Morgan Lewis (sell-side)Edgemont Partners (sell-side) |
| Aug 2026 | MAIN5 | – | Astrix | Acquisition | Announced | – | Pharma Services+1 | Gibson Dunn (buy-side) |
| Aug 2026 | assets, business operations and customer relationships | – | NueCell Bio | Asset sale | Announced | – | Pharma Services+1 | Goodwin (buy-side) |
| Aug 2026 | Relevate Health | Mountaingate Capital | – | Acquisition | Completed | – | Pharma Services+2 | Latham & Watkins (sell-side) |
| Jul 2026 | PANTHERx Rare | Nautic Partners | Warburg Pincus-led investor group | Acquisition | Announced | – | Healthcare Services+2 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Ropes & Gray (sell-side)J.P. Morgan (buy-side)Cleary Gottlieb Steen & Hamilton (buy-side) |
| Jul 2026 | Lannett | – | Aurobindo | Acquisition | Completed | 250.0 | Pharma+1 | Raymond JamesSullivan & Cromwell (buy-side) |
| Jul 2026 | Commissioning Agents | – | JLL Partners | Acquisition | Completed | – | Pharma Services+1 | Stout (sell-side) |
| Jul 2026 | OptiMed Health Partners | – | Lee Equity Partners | Stake | Completed | – | Pharma Services+1 | Edgemont Partners (sell-side) |
| Jul 2026 | Asembia | – | Peak Rock Capital | Acquisition | Completed | – | Pharma Services+2 | BofA Securities (sell-side)McDermott Will & Schulte (sell-side)Kirkland & Ellis (buy-side)Houlihan Lokey (buy-side)Bass, Berry & Sims (buy-side) |
| May 2026 | AmbioPharm | – | CordenPharma | Acquisition | Announced | – | Pharma Services+2 | Kirkland & EllisBNP Paribas (sell-side)Latham & Watkins (buy-side) |
| May 2026 | MacroGenics GMP manufacturing site and CDMO operations | MacroGenics | Bora Pharmaceuticals Co. | Asset sale | Completed | 122.5 | Pharmaceutical Manufacturing+1 | Moelis & Company (sell-side)Sidley Austin (sell-side)Covington & Burling (sell-side)Jones Day (buy-side) |
| May 2026 | CDMO and Cell Solutions businesses of Charles River Laboratories | Charles River Laboratories International | GI Partners | Asset sale | Completed | – | Pharma Services+2 | Moelis & Company (buy-side)Ropes & Gray (buy-side) |
| Apr 2026 | Certara Regulatory and Medical Writing business | Certara | Veristat | Asset sale | Announced | 135.0 | Pharma Services+1 | Perella Weinberg Partners (sell-side)Troutman Pepper Locke (sell-side)Guggenheim Securities (buy-side)McDermott Will & Schulte (buy-side) |
| Apr 2026 | EpiVax | – | SV Health Investors | Acquisition | Announced | – | Pharma Services+2 | Morgan Lewis (buy-side) |
| Apr 2026 | Modersys (fka SmartFactory Rx) | Applied Materials | TELEO Capital | Asset sale | Completed | – | Industrial Software+1 | Lazard |
| Apr 2026 | Celerion | H.I.G. Capital affiliate | THL Partners | Acquisition | Announced | – | Pharma Services+2 | LazardKirkland & Ellis (buy-side)Paul, Weiss (buy-side) |
| Mar 2026 | Syntegon | CVC Capital Partners | Apollo | Stake | Announced | – | Manufacturing+2 | Willkie Farr & Gallagher (sell-side)Sidley Austin (buy-side) |
| Mar 2026 | Owen Mumford Holdings | – | Embecta Corp. | Acquisition | Pending | 132.2 | Medtech+1 | Forvis Mazars (South Africa) (sell-side)Mills & Reeve (sell-side)J.P. Morgan (buy-side)A&O Shearman (buy-side) |
| Mar 2026 | Lonza Capsules & Health Ingredients division | Lonza Group AG | Lone Star Funds | Asset sale | Announced | – | Pharmaceutical Manufacturing+2 | Kirkland & Ellis (buy-side) |
| Mar 2026 | Manufacturing facility in Phoenix, AZ | Bristol Myers Squibb | Rovi | Asset sale | Completed | – | Pharmaceutical Manufacturing+1 | William Blair |
| Feb 2026 | Laysan Bio | – | Gannet BioChem | Acquisition | Announced | – | Pharma Services+2 | Goodwin (buy-side) |
| Feb 2026 | Broth | – | Supreme Group | Acquisition | Announced | – | Advertising and marketing+1 | Edgemont Partners (sell-side) |
| Jan 2026 | SubjectWell | – | – | Merger | Announced | – | Clinical Trial Services | Stout (sell-side)Fairmount Partners (buy-side) |
| Jan 2026 | Hayden Consulting Group | – | BGB Group | Acquisition | Completed | – | Pharma Services+2 | Morgan Lewis (sell-side)Clearsight Advisors (sell-side) |
| Jan 2026 | Nivagen Pharmaceuticals | – | PAI Pharma | Acquisition | Announced | – | Pharmaceutical Manufacturing+1 | Bourne Partners (buy-side)Kirkland & Ellis (buy-side)KPMG (buy-side) |
| Jan 2026 | Evidinno Outcomes Research | – | United BioSource | Acquisition | Completed | – | Pharma Services+2 | Fairmount Partners (sell-side) |
| Sep 2025 | Zentiva | Advent International | GTCR | Acquisition | Announced | – | Pharma+1 | Goldman Sachs (sell-side)PJT Partners (sell-side)Freshfields (sell-side)Barclays (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Jun 2025 | Felix Pharmaceuticals Pvt | – | Advent International | Stake | Announced | – | Animal Health+2 | A&L Goodbody LLPLincoln International (sell-side)Guggenheim Securities (buy-side) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built